This Week's Exclusive

​Hepatocellular carcinoma (HCC), the most common type of primary liver cancer, is a challenging condition to treat, with reported five-year survival rates ranging from 30% to 50%. Recently, the FDA approved cabozantinib (Cabometyx®, Exelixis, Inc.) as second-line treatment for patients with HCC previously treated with sorafenib. Thomas A. Abrams, MD, Assistant Professor of Medicine at Harvard Medical School, spoke with i3 Health about cabozantinib's approval and about the var...

Top Oncology Stories

Wednesday, February 20, 2019
For many patients with cancer, treatment resistance develops, leaving cancerous cells to continue to proliferate. Viewing the capability of cancer cells to develop resistance to...
Wednesday, February 20, 2019
The immune system's response to melanoma both improves survival for untreated patients and predicts a patient's response to immune checkpoint blockade therapy. A British study ...
Tuesday, February 19, 2019
Patients with small cell lung cancer (SCLC) often do not respond to immune checkpoint blockade therapy alone. However, researchers at the University of Texas MD Anderson Can...
Tuesday, February 19, 2019
​A phase 3 clinical trial has found that in previously untreated patients with advanced renal-cell carcinoma (RCC), avelumab plus axitinib improves progression-free survival an...
Monday, February 18, 2019
Researchers report that glyphosate, the herbicide commonly found in Roundup® (Monsanto Technology, LLC), which is used as a pesticide on produce, significantly increases the ris...

Expert Perspectives

​Hepatocellular carcinoma (HCC), the most common type of primary liver cancer, is a challenging condition to treat, with reported five-year survival rates ranging from 30% to 50%. Recently, the FDA approved cabozantinib (Cabometyx...
​In their previous research, Virginia F. Borges, MD, MMSc, and colleagues identified an increased risk of metastasis for women diagnosed with breast cancer within five years after giving birth. However, in their latest study, ...
Breast cancer survivors are at an increased risk of developing a myriad of symptoms, including anxiety, depression, pain, and fatigue. Acupressure has been practiced for thousands of years as part of traditional Chinese medici...
In an interview with i3 Health, Mark A. Socinski, MD, shares insights regarding the recent FDA approval of atezolizumab (Tecentriq®, Genentech, Inc.) in combination with carboplatin/paclitaxel/bevacizumab for patients with previou...
​Brain and spinal cord tumors are the second most common cancers in children, accounting for 1 out of 4 childhood cancers. Despite intensive treatment, children with histologically diagnosed high-risk medulloblastoma, supraten...

Original Research

In order to accurately recognize the continuing medical education (CME) needs and preferences of urology/oncology health care providers, i3 Health administered a survey to participants at the 66th Society of Government Service ...
In order to identify the continuing medical education needs and preferences of hematology/oncology fellows, i3 Health administered a survey to participants at several live CME-certified visiting faculty meetings. i3 Health inte...
Chronic myeloid leukemia (CML) accounts for 15% of all adult leukemias and is characterized by heterogenous clinical manifestations. In recent years outcomes for patients with CML have greatly improved, in part due to the a...
Many patients with cancer who receive systemic therapy experience cancer treatment-related cognitive impairment, commonly referred to as "chemo brain." Chemo brain is characterized by the inability to remember certain thing...
The incidence of suicide among patients with cancer in the United States is twice that of the general population. Studies demonstrate that demoralization, defined as lowered morale and perceived incapacity to cope, is stron...

© Copyright 2019 i3 Health. All rights reserved.